ANTI — Antigenics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Antigenics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	1996 December 31st	1997 December 31st	1998 December 31st	1999 December 31st	2000 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K405	10-K405	10-K405	10-K
Standards:	—	—	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-8.03	-17	-18.2	-14.1	-18
Depreciation
Non-Cash Items	0.808	3.78	1.35	2.52	-1.83
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-1.31	1.38	3.85	-2.12	0.955
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities	-7.59	-10.7	-12.2	-13.1	-18.3
Capital Expenditures	-0.256	-0.352	-1.96	-0.377	-0.401
Purchase of Fixed Assets
Other Investing Cash Flow Items	-33	8.85	19.4	0.328	7.91
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-33.2	8.5	17.4	-0.049	7.51
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	37.2	0.043	4.1	13.3	7.48
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-3.6	-2.15	9.31	0.19	-3.27